Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.

Kim H, Samuel S, Totenhagen JW, Warren M, Sellers JC, Buchsbaum DJ.

J Vis Exp. 2015 Apr 18;(98). doi: 10.3791/52641.

PMID:
25938718
2.

S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.

Che P, Yang Y, Han X, Hu M, Sellers JC, Londono-Joshi AI, Cai GQ, Buchsbaum DJ, Christein JD, Tang Q, Chen D, Li Q, Grizzle WE, Lu YY, Ding Q.

Sci Rep. 2015 Feb 13;5:8453. doi: 10.1038/srep08453.

3.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425.

4.

Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Kim H, Folks KD, Guo L, Sellers JC, Fineberg NS, Stockard CR, Grizzle WE, Buchsbaum DJ, Morgan DE, George JF, Zinn KR.

Mol Imaging. 2011 Jun;10(3):153-67.

5.

Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2011 Apr;121(1):193-9. doi: 10.1016/j.ygyno.2010.11.046.

PMID:
21211830
6.

KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.

McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang ZQ, Grizzle WE, Stockard CR, Nash KT, Buchsbaum DJ.

Clin Exp Metastasis. 2010 Dec;27(8):591-600. doi: 10.1007/s10585-010-9349-5.

7.

Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.

Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR.

Cancer Res. 2008 Oct 15;68(20):8369-76. doi: 10.1158/0008-5472.CAN-08-1771.

8.

Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.

DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5535s-5543s.

9.

Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.

Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ.

Gene Ther. 2007 Jul;14(14):1111-9.

PMID:
17495948
10.

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.

J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300.

PMID:
17114015
11.

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.

Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8773-81.

12.
13.

A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates.

Neill JD, Duck LW, Sellers JC, Musgrove LC.

Biochem Biophys Res Commun. 2001 Apr 13;282(4):1012-8.

PMID:
11352653
14.

Dual intracellular pathways in gonadotropin releasing hormone (GNRH) induced desensitization of luteinizing hormone (LH) secretion.

Cassina MP, Musgrove LC, Duck LW, Sellers JC, Neill JD.

Life Sci. 1999;64(24):2215-23.

PMID:
10374911
16.
17.

Potential Regulatory Roles for G Protein-Coupled Receptor Kinases and β-Arrestins in Gonadotropin-Releasing Hormone Receptor Signaling.

Neill JD, Duck LW, Musgrove LC, Sellers JC.

Endocrinology. 1998 Apr 1;139(4):1781-1788. doi: 10.1210/endo.139.4.5868. No abstract available.

PMID:
28204187
18.

Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism.

Layman LC, Cohen DP, Jin M, Xie J, Li Z, Reindollar RH, Bolbolan S, Bick DP, Sherins RR, Duck LW, Musgrove LC, Sellers JC, Neill JD.

Nat Genet. 1998 Jan;18(1):14-5. No abstract available.

PMID:
9425890
19.

Epitope-tagged gonadotropin-releasing hormone receptors heterologously-expressed in mammalian (COS-1) and insect (Sf9) cells.

Neill JD, Sellers JC, Musgrove LC, Duck LW.

Mol Cell Endocrinol. 1997 Mar 28;127(2):143-54.

PMID:
9099910
20.

Potential role for a regulator of G protein signaling (RGS3) in gonadotropin-releasing hormone (GnRH) stimulated desensitization.

Neill JD, Duck LW, Sellers JC, Musgrove LC, Scheschonka A, Druey KM, Kehrl JH.

Endocrinology. 1997 Feb;138(2):843-6.

PMID:
9003025

Supplemental Content

Loading ...
Support Center